BlueRock Therapeutics

BlueRock Therapeutics is one of the largest biotech companies in Canada. It is committed to developing cell treatments to treat a variety of incurable illnesses. The BlueRock unique cell+gene platform, which was founded in 2016 and bought by Bayer in 2019, provides cell therapies for the three therapeutic areas of neurology, cardiology, and immunology. Particularly, BlueRock Therapeutics has achieved significant strides in the treatment of autoimmune illnesses, Parkinson's disease, and heart failure.

BlueRock creates cell therapies to restore injured or deteriorated tissue utilizing their Cell plus Gene platform. Engineering microglia for Parkinson's Disease and other neurological illnesses are the main goals of BlueRock's neurology pipeline. Their cardiology pipeline involves cell treatment employing cardiomyocytes for heart failure. The company is developing macrophage cell treatments for autoimmune disorders. Ex vivo engineering is a technique employed by BlueRock to allow cells to create therapeutically useful enzymes, antibodies, and other proteins.

BlueRock has revolutionized and scaled methods for producing real cell types in the fields of neurology, cardiology, and immunology. Its work is based on the study of some of the top minds in the field of induced pluripotent stem cell (iPSC) biology.

Founded: 2016
Headquarters: Toronto, Canada
Website: https://bluerocktx.com/